TVTX insider ownership: who sold, why, and what they still hold

What stands out

Selling picked up in the last 90 days: officers and directors sold 1.06M shares, against an average of 339K per 90 days earlier in the period. Most of it was Eric Dube (400K shares in the last 90 days) and Peter Heerma (283K shares in the last 90 days); 99.9% of these sales were under disclosed plans.Eric Dube: largest recent sale, Sep 17, 2026 · Peter Heerma: largest recent sale, Sep 16, 2026

A share of stake is shown for 0 of the 11 officers and directors who sold. 16 are left out

Left out: Eric Dube, Peter Heerma, William Rote, Christopher Cline, Elizabeth Reed, Jula Inrig, Jeffrey Meckler, Gary Lyons, Timothy Coughlin, Sandra Calvin, Roy Baynes, John Orwin, Ron Squarer, Sandra Poole, Suzanne Bruhn and Brinkley Williams (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Eric Dube

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$41.3MDisclosed plan

Peter Heerma

EVP, Chief Commercial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$19.0M97% planned, 3% to cover taxes

William Rote

Chief Research Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$16.4MDisclosed plan

Elizabeth Reed

Chief Legal Officer and GC

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$7.0M97% planned, 3% to cover taxes

Jula Inrig

EVP, Head of R&D & CMO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.2M96% planned, 4% to cover taxes

All 11 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 17, 20262 executives sold 117K shares ($7.5M) under a disclosed trading plan. 117K shares came in from vesting or option exercises the same day, so their combined holdings rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Eric Dube Chief Executive Officer, Director	108,493	$64.61	n/a	n/a	Sep 17, 2026	Sep 17, 2026
Peter Heerma EVP, Chief Commercial Officer	8,282	$65.07	n/a	n/a	Sep 17, 2026	Sep 17, 2026

Sep 16, 20263 executives sold 481K shares ($30.5M) under a disclosed trading plan. 481K shares came in from vesting or option exercises the same day, so their combined holdings rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Eric Dube Chief Executive Officer, Director	195,841	$63.45	n/a	n/a	Sep 16, 2026	Sep 17, 2026
Peter Heerma EVP, Chief Commercial Officer	172,717	$63.43	n/a	n/a	Sep 16, 2026	Sep 17, 2026
William Rote Chief Research Officer	112,850	$63.33	n/a	n/a	Sep 16, 2026	Sep 17, 2026

Sep 15, 20267 executives sold 432K shares ($26.9M) under a disclosed trading plan. 347K shares came in from vesting or option exercises the same day, so their combined holdings fell by 85K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Peter Heerma EVP, Chief Commercial Officer	102,190	$62.26	n/a	n/a	Sep 15, 2026	Sep 17, 2026
William Rote Chief Research Officer	96,198	$62.25	n/a	n/a	Sep 15, 2026	Sep 17, 2026
Eric Dube Chief Executive Officer, Director	95,666	$62.26	n/a	n/a	Sep 15, 2026	Sep 17, 2026
Christopher Cline Chief Financial Officer	50,508	$62.34	n/a	n/a	Sep 15, 2026	Sep 17, 2026
Jula Inrig EVP, Head of R&D & CMO	44,674	$62.34	n/a	n/a	Sep 15, 2026	Sep 17, 2026
Elizabeth Reed Chief Legal Officer and GC	37,500	$62.34	n/a	n/a	Sep 15, 2026	Sep 17, 2026
Sandra Calvin SVP, Chief Accounting Officer	5,375	$62.33	n/a	n/a	Sep 15, 2026	Sep 17, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Travere Therapeutics, Inc. CEO selling stock?

Yes. Eric Dube sold 887K shares ($41.3M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Travere Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 99% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 1% were to cover taxes. A trading plan schedules sales in advance.

Are any Travere Therapeutics, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold11 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Eric Dube Chief Executive Officer, Director	$41.3M 887K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Peter Heerma EVP, Chief Commercial Officer	$19.0M 313K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
William Rote Chief Research Officer	$16.4M 293K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Elizabeth Reed Chief Legal Officer and GC	$7.0M 163K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
Jula Inrig EVP, Head of R&D & CMO	$5.2M 102K shares	Not confirmed share of stake is being verified. Why	96% under a disclosed plan, 4% to cover taxes
Christopher Cline Chief Financial Officer	$4.6M 91K shares	Not confirmed share of stake is being verified. Why	94% under a disclosed plan, 6% to cover taxes
Sandra Calvin SVP, Chief Accounting Officer	$4.2M 109K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
Roy Baynes Director	$2.5M 62K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Jeffrey Meckler Director	$1.7M 28K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Timothy Coughlin Director	$1.3M 31K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Gary Lyons Director	$961K 18K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 16 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Eric Dube

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Eric Dube are complete.

Chief Executive Officer, Director

n/a

−887K

n/a

Vesting, gifts, unvested awards and holding lines for Eric Dube

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eric Dube are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
360,000	$8.93	Jan 30, 2034	$20.2M
260,000	$20.46	Jan 31, 2035	$11.6M
303,600	$33.09	Jan 31, 2036	$9.7M

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Peter Heerma

EVP, Chief Commercial Officer

n/a

−313K

n/a

Vesting, gifts, unvested awards and holding lines for Peter Heerma

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Peter Heerma are complete; balances and unit counts will be added when the check is finished.

−1.1Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
500	$26.88	Jan 20, 2031	$19K
44,837	$22.40	Jan 30, 2033	$1.9M
28,474	$8.93	Jan 30, 2034	$1.6M
58,000	$20.46	Jan 31, 2035	$2.6M
69,640	$33.09	Jan 31, 2036	$2.2M

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

William Rote

Chief Research Officer

n/a

−293K

n/a

Vesting, gifts, unvested awards and holding lines for William Rote

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William Rote are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
65,000	$8.93	Jan 30, 2034	$3.6M
58,000	$20.46	Jan 31, 2035	$2.6M
53,570	$33.09	Jan 31, 2036	$1.7M

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Christopher Cline

Chief Financial Officer

n/a

−91K

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Cline

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Cline are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
65,000	$8.93	Jan 30, 2034	$3.6M
58,000	$20.46	Jan 31, 2035	$2.6M
75,000	$33.09	Jan 31, 2036	$2.4M

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Elizabeth Reed

Chief Legal Officer and GC

n/a

−163K

n/a

Vesting, gifts, unvested awards and holding lines for Elizabeth Reed

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elizabeth Reed are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Jula Inrig exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
65,000	$8.93	Jan 30, 2034	$3.6M
58,000	$20.46	Jan 31, 2035	$2.6M
66,960	$33.09	Jan 31, 2036	$2.1M

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Jula Inrig

EVP, Head of R&D & CMO

n/a

−102K

n/a

Vesting, gifts, unvested awards and holding lines for Jula Inrig

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jula Inrig are complete; balances and unit counts will be added when the check is finished.

−468gifted (net of own trusts)

Some sales match sales reported by Elizabeth Reed exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
34,500	$22.40	Jan 30, 2033	$1.5M
43,605	$8.93	Jan 30, 2034	$2.4M
100,000	$20.46	Jan 31, 2035	$4.5M
75,000	$33.09	Jan 31, 2036	$2.4M

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Jeffrey Meckler

Director

n/a

−28K

n/a

Vesting, gifts, unvested awards and holding lines for Jeffrey Meckler

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Meckler are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,500	$6.82	May 7, 2034	$1.1M
19,500	$21.15	May 15, 2035	$856K
12,000	$42.26	May 19, 2036	$274K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Gary Lyons

Director

n/a

−18K

n/a

Vesting, gifts, unvested awards and holding lines for Gary Lyons

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gary Lyons are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,500	$6.82	May 7, 2034	$1.1M
19,500	$21.15	May 15, 2035	$856K
12,000	$42.26	May 19, 2036	$274K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Timothy Coughlin

Director

n/a

−31K

n/a

Vesting, gifts, unvested awards and holding lines for Timothy Coughlin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Timothy Coughlin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,500	$6.82	May 7, 2034	$1.1M
19,500	$21.15	May 15, 2035	$856K
12,000	$42.26	May 19, 2036	$274K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Sandra Calvin

SVP, Chief Accounting Officer

n/a

−109K

n/a

Vesting, gifts, unvested awards and holding lines for Sandra Calvin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sandra Calvin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,750	$22.40	Jan 30, 2033	$160K
12,500	$8.93	Jan 30, 2034	$702K
17,875	$20.46	Jan 31, 2035	$797K
20,160	$33.09	Jan 31, 2036	$645K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Roy Baynes

Director

n/a

−62K

n/a

Vesting, gifts, unvested awards and holding lines for Roy Baynes

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Roy Baynes are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,750	$17.11	May 16, 2033	$324K
9,750	$6.82	May 7, 2034	$568K
19,500	$21.15	May 15, 2035	$856K
12,000	$42.26	May 19, 2036	$274K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

John Orwin

Director

n/a

Vesting, gifts, unvested awards and holding lines for John Orwin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Orwin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,500	$6.82	May 7, 2034	$1.1M
19,500	$21.15	May 15, 2035	$856K
12,000	$42.26	May 19, 2036	$274K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Ron Squarer

Director

n/a

Vesting, gifts, unvested awards and holding lines for Ron Squarer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ron Squarer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,500	$6.82	May 7, 2034	$1.1M
19,500	$21.15	May 15, 2035	$856K
12,000	$42.26	May 19, 2036	$274K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Sandra Poole

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sandra Poole

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sandra Poole are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,500	$6.82	May 7, 2034	$1.1M
19,500	$21.15	May 15, 2035	$856K
12,000	$42.26	May 19, 2036	$274K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Suzanne Bruhn

Director

n/a

Vesting, gifts, unvested awards and holding lines for Suzanne Bruhn

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Suzanne Bruhn are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,500	$6.82	May 7, 2034	$1.1M
19,500	$21.15	May 15, 2035	$856K
12,000	$42.26	May 19, 2036	$274K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Brinkley Williams

Director

n/a

Vesting, gifts, unvested awards and holding lines for Brinkley Williams

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brinkley Williams are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,500	$6.82	May 7, 2034	$1.1M
19,500	$21.15	May 15, 2035	$856K
12,000	$42.26	May 19, 2036	$274K

Estimate: options held × ($65.07 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Holdings and share of stake for Travere Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$104M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $104M across 2,096,904 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $103M · 99%

The lighter segment is sales with no plan disclosed in the filing ($1.5M), including tax-related sales outside a plan.

Taxes

$11.3M of sales (10.8%) cite tax obligations in their footnotes, $9.7M of them also under a plan. Example: Christopher Cline, Sep 2, 2026

Charitable gifts · 1.5K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Eric Dube Chief Executive Officer, Director	887K	$41.3M	100%	40%	Oct 28, 2025 to Sep 17, 2026
Peter Heerma EVP, Chief Commercial Officer	313K	$19.0M	97%	18%	Oct 28, 2025 to Sep 17, 2026
William Rote Chief Research Officer	293K	$16.4M	100%	16%	Dec 24, 2025 to Sep 16, 2026
Elizabeth Reed Chief Legal Officer and GC	163K	$7.0M	97%	7%	Jan 20, 2026 to Sep 15, 2026
Jula Inrig EVP, Head of R&D & CMO	102K	$5.2M	96%	5%	Dec 24, 2025 to Sep 15, 2026
Christopher Cline Chief Financial Officer	91K	$4.6M	94%	4%	Dec 1, 2025 to Sep 15, 2026
Sandra Calvin SVP, Chief Accounting Officer	109K	$4.2M	97%	4%	Nov 4, 2025 to Sep 15, 2026
Roy Baynes Director	62K	$2.5M	100%	2%	Apr 6, 2026 to Jun 12, 2026
Jeffrey Meckler Director	28K	$1.7M	100%	2%	May 4, 2026 to Sep 10, 2026
Timothy Coughlin Director	31K	$1.3M	100%	1%	Oct 31, 2025 to Jun 12, 2026
Gary Lyons Director	18K	$961K	100%	0.9%	Apr 14, 2026 to Aug 18, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$4.5M	$4.5M	$0	$0
Nov 2025	$2.4M	$2.4M	$0	$0
Dec 2025	$4.3M	$4.3M	$0	$0
Jan 2026	$2.2M	$2.2M	$0	$0
Feb 2026	$7.0M	$5.9M	$1.1M	$0
Mar 2026	$281K	$281K	$0	$0
Apr 2026	$11.2M	$10.9M	$303K	$0
May 2026	$4.6M	$4.5M	$101K	$0
Jun 2026	$726K	$726K	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$633K	$633K	$0	$0
Sep 2026	$66.4M	$66.3M	$43K	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: $104M sold, after almost none in the past 5 years. 11 insiders sold; the average is 8 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	2.10M	11	$104M
Oct 13, 2025 1 year earlier	292K	8	$6.3M
Oct 13, 2024 2 years earlier	178K	9	$2.1M
Oct 14, 2023 3 years earlier	55K	7	$1.1M
Oct 14, 2022 4 years earlier	127K	7	$3.5M
Oct 14, 2021 5 years earlier	299K	7	$7.7M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty16 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Travere Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology551 filings on record, 72 filed in the 12-month period, and how we read them

All 551 Forms 3, 4 and 5 on record for Travere Therapeutics, Inc. (SEC CIK 1438533), filed from Jun 6, 2012 to Sep 17, 2026; 72 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (16)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Steve Aselage	May 12, 2022	166,419 shares, last reported balance as of May 11, 2022
Laura Clague	May 12, 2022	35,655 shares, last reported balance as of May 11, 2022
Noah Rosenberg	Aug 17, 2021	47,614 shares, last reported balance as of Aug 17, 2021
Neil McFarlane	May 16, 2019	26,988 shares, last reported balance as of May 16, 2019
John Kozarich	May 10, 2019	29,000 shares, last reported balance as of May 8, 2019
Alvin Shih	Sep 2, 2016	158,334 shares, last reported balance as of Sep 1, 2016
Cornelius Golding	May 19, 2016	29,000 shares, last reported balance as of May 18, 2016
Jensen Valeur	Feb 2, 2016	100,000 shares, last reported balance as of Feb 1, 2016
Broadfin Healthcare Master Fund Ltd	Jan 30, 2015	2,658,854 shares, last reported balance as of Jan 13, 2015
Horacio Plotkin	Dec 16, 2014	91,767 shares, last reported balance as of Dec 12, 2014
Steven Richardson	Dec 9, 2014	129,165 shares, last reported balance as of Nov 21, 2014
Martin Shkreli	Nov 24, 2014	1,765,168 shares, last reported balance as of Nov 21, 2014
Jeffrey Paley	Aug 18, 2014	51,665 shares, last reported balance as of Aug 14, 2014
Marc Panoff	Feb 28, 2014	221,100 shares, last reported balance as of Feb 24, 2014
Opaleye GP LLC	Jan 3, 2014	2,097,671 shares, last reported balance as of Dec 24, 2013
Ruth Shepley	Jun 6, 2012	49,000,000 shares, last reported balance as of Oct 5, 2007

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Travere Therapeutics, Inc. insiders sold $104M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Travere Therapeutics, Inc. CEO selling stock?

Why are Travere Therapeutics, Inc. insiders selling?

Are any Travere Therapeutics, Inc. insiders buying?

The evidence

Taxes

Charitable gifts · 1.5K shares

Sales by month